Quantcast

Latest GlaxoSmithKline Stories

2014-05-19 20:21:48

LONDON, May 19, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist (also known as an anticholinergic), umeclidinium 'UMEC' 62.5mcg (Incruse(TM)( )Ellipta(®)) and UMEC 125mcg, to the inhaled corticosteroid and long-acting beta2 agonist combination medicine, fluticasone proprionate and salmeterol 'FSC...

2014-05-17 23:03:15

“Since October 2007, the cost of brand-name medicines has soared, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure, and even erectile dysfunction,” according to an article published on Businessweek.com on May 8, 2014 (1). polyDNA reviews the article and recommends Gene-Eden-VIR and Novirin, affordable natural antiviral products, that help the immune system target latent viruses. Rochester, NY (PRWEB) May 17,...

2014-05-16 23:10:14

Anger leaves “your weary body more vulnerable to viruses and illness,” according to an article published on March 14, 2014 on TheAustralian.com.au (1). polyDNA recommends that people who become angry easily ask their doctors about Gene-Eden-VIR and Novirin, natural products designed to boost the immune system against latent viral pathogens. Rochester, NY (PRWEB) May 16, 2014 polyDNA has learned that “A study in European Heart Journal by the Harvard School of Public Health warns...

2014-05-15 12:34:27

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Antibacterial Drugs: World Market Prospects 2013-2023http://www.reportbuyer.com/pharma_healthcare/generic_drugs/antibacterial_drugs_world_market_prospects.html Report DetailsDiscover new trends, opportunities and revenue prospects for bacteria-killing medicinesWhere's the antibiotics market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues...

2014-05-15 08:31:23

CARLSBAD, Calif., May 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "We have had a very productive alliance with GlaxoSmithKline, from which we have advanced three antisense drugs in our...

2014-05-13 23:14:12

In its latest May 2014 survey, polyDNA found that 68% of respondents did not know if the same antiviral treatments are used against genital and oral herpes infections. polyDNA reviews the literature and recommends Gene-Eden-VIR and Novirin, natural antivirals, with a formula proven to reduce herpes symptoms. Rochester, NY (PRWEB) May 13, 2014 polyDNA’s latest survey found that 68% of respondents did not know if the same antiviral treatments are used against both genital and oral herpes...

2014-05-13 12:30:41

LONDON, May 13, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:China Pharmaceuticals and Healthcare Report Q2 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/china_pharmaceuticals_healthcare_report_q2_2013.html Includes 3 FREE quarterly updatesBMI View: Strong sales growth reported by multinational pharmaceutical firms in China over the courseof 2013 is directly in line with our longtermoptimism towards the country's pharmaceutical and...

2014-05-12 23:11:15

polyDNA’s newest survey for the month of May discovered that 36% of respondents with arthritis wanted to know if EBV is the cause of their disease. polyDNA reviews the literature on this topic and recommends Gene-Eden-VIR and Novirin against EBV, which is linked to arthritis. Rochester, NY (PRWEB) May 12, 2014 polyDNA’s latest survey revealed that 36% of respondents with arthritis wanted to know if EBV is the cause of their disease. One study found that “In latent and replicating...

2014-05-09 12:22:38

For more information about this release, please scroll to bottom. NEW YORK, May 9, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Zoetis Inc. (NYSE: ZTS), Aetna Inc. (NYSE: AET) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:...

2014-05-07 23:05:38

The U.S. Food and Drug Administration (FDA) approved the start of Phase II of required clinical studies for a new antibiotic, GSK944, developed by the Defense Threat Reduction Agency’s Chemical and Biological Technologies Department (DTRA CB) and its industry partner GlaxoSmithKline. Fort Belvoir, VA (PRWEB) May 07, 2014 The U.S. Food and Drug Administration (FDA) approved the start of Phase II of required clinical studies for a new antibiotic, GSK944, developed by the Defense Threat...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related